ECCO 2026

Precision medicine - from a static to a dynamic system

IL-23 - is this the good-bye from systemic therapy?

Early treatment concepts with infliximab

What is the best post-operative strategy in CD?

Deeper endpoints in clincial trials and RW

Fistulizing disease - what can we do better?

Update on upadacitinib vs. risankizumab after anti-TNF…

Diet as prevention and early intervention in Crohn’s…

Evolving landscape of anti-fibrotic therapy in IBD

Long-term data on colorectal cancer risk in modern IBD…

Should we stop thiopurines in IBD patients who are…

Stop of thiopurines in patients on subcutaneous…

Switching to subcutaneous infliximab is safe as a…

What is the best treatment approach in IBD?

Molecular medicine driving treatment decisioning!?

Θα πρέπει να σταματήσουμε τις θειοπουρίνες σε ασθενείς…

Top-down- versus Step-up-Therapie beim Morbus Crohn

Was ist der beste Therapieansatz bei CED?

Should we prevent or treat post-operative recurrence in…

Do we need immediate postoperative prophylaxis?

Long-term risankizumab persistence

Early use of infliximab positively influences longterm…

LIR!C 10 yrs FUP: Is there a benefit for surgery?

Top-down vs. step-up therapy in CD

Is onmiddellijke postoperatieve preventie nodig?

JAK-STAT Hemmung zur Fistel-Therapie

Früher Einsatz von Infliximab verbessert das…

Faut-il prévenir ou traiter la récidive postopératoire…

LIR!C — suivi 10 ans: bénéfice de la chirurgie?

Combination therapy with tofacitinib and…

Treat-2-target strategy in UC

Long term outcomes after appendicectomy in UC (5 year…

ASUC: smarter use of third-line rescue therapy

Pouch surgery: only for expert centers

Pouchchirurgie: enkel voor expertisecentra

Tofacitinib-Steroid-Kombination bei ASUC

Strategia treat-to-target nella colite ulcerosa

Resultados a largo plazo tras apendicectomía en colitis…

Effetto steroid-sparing di filgotinib nella colite…

The risk of colorectal neoplasia in IBD

Long-term outcomes of IL‑23 inhibitors

Risque de cancer colorectal dans les MICI

Obefazimod come agente antifibrotico

Guselkumab may improve and prevent extraintestinal…

Histo-endoscopic outcomes of upadacitinib in CD

Ustekinumab is effective and safe for paediatric…

Outside the gut - efficacy uf guselkumab in…

UPA vs RISA in Crohn’s disease – a decision dilemma

Guselkumab a objawy pozajelitowe

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Guselkumab può migliorare e prevenire le manifestazioni…

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

Short-term effectiveness and safety of Mirikizumab in…

Histo-endoscopic outcomes of guselkumab in UC

Early and durable response with guselkumab

Etrasimod in the milder moderate UC patients

Efficacy and safety of vedolizumab + upadacitinib as…

Mirikizumab is able to induce disease clearence in…

Short term transmural healing detected by US in CD…

Vedolizumab combined with upadacitinib vs Vedolizumab…

Does colectomy reduce the risk of death in UC?

Long-term efficacy and safety of risankizumab in UC

Early symptomatic response with IL-23 blockers

Est-ce que la colectomie réduit le risque de décès dans…

Vedolizumab combinado con upadacitinib vs Vedolizumab…

Efficacia e sicurezza a lungo termine di risankizumab…

Efficacia di Etrasimod in pazienti affetti da colite…

Frühes symptomatisches Ansprechen unter IL-23-Blockade

Valutazione a breve termine della guarigione…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Appendectomy - a new therapeutic option in UC

Impact of icotrokinra on biomarkers in UC

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

B-cells step into the spotlight

The STENOVA Trial. Ontunisertib shows promising results…

Icotrokinra and systemic inflammatory burden in UC

AGMB-129, Ontunisertib, new MoA in patients with…

L’accumulo di cellule citotossiche CD4+ caratterizza la…

Apendektomie - eine neue Therapieoption bei Colitis…

תאי B במרכז העניינים

Ikotrokinkra a stan zapalny w colitis ulcerosa

Impact de l’icotrokinra sur les biomarqueurs dans la…

AGMB-129, Ontunisertib, nueva terapia para pacientes…

Ontunisertib – ALK5-Blockade bei fistulierendem Morbus…

ADHD and autism in IBD – the same or different story?

IBDMED going global!

IBDMED מעבר לאזור הים התיכון